Dewpoint Therapeutics Inc. has described TAR DNA-binding protein 43 (TARDBP; TDP-43) modulators reported to be useful for the treatment of traumatic brain injury, frontotemporal dementia and amyotrophic lateral sclerosis.

Work at Erciyes University has led to the discovery of antimicrobial peptides with potential for the treatment of bacterial and fungal infections.

Jacobio Pharmaceuticals Co. Ltd. has reported new fused tetracyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized new mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of urticaria.

Janssen Pharmaceutica NV has identified new compounds reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19).

Albireo Ltd. has patented new benzothia(di)azepine compounds acting as ileal sodium/bile acid cotransporter (SLC10A2; IBAT; ASBT) and/or sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors reported to be useful for the treatment of diabetes, cardiovascular, gastrointestinal, liver and renal disorders.

Five years after the COVID-19 pandemic virtually locked down the U.S. government and society in general, the Patent Trial and Appeal Board (PTAB) is shedding the last vestiges of those days.

E3 ubiquitin-protein ligase RNF31 inhibitors are disclosed in a Flindr Therapeutics BV patent as potentially useful for the treatment of cancer.

Shanghai Yuyao Biotech Ltd. has identified new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer.

Breakpoint Therapeutics GmbH patents describe new DNA polymerase θ (POLQ, POLθ) inhibitors potentially useful for the treatment of cancer.